EBS vs MRNA · rev $390.4M vs rev $145.0M
Emergent Biosolutions Inc (EBS) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Latest reported EBS revenue for 2026-06-30 was $390.4M. Net income was -$173.4M. EBS currently screens at market cap $416.4M.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
EBS currently screens at market cap $416.4M. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the EBS and MRNA stock pages for the full models.
Not investment advice.